Now showing items 1-3 of 3

    • CTCs-derived xenograft development in a triple negative breast cancer case 

      Pereira Veiga, Tais; Abreu, Manuel; Robledo, Diego; Matias-Guiu, Xavier; Santacana Espasa, Maria; Sanchez Piñon, Laura Elena; Cueva, Juan; Palacios, Patricia; Abdulkader, Ihab; López-López, Rafael; Muinelo-Romay, Laura; Costa, Clotilde (Wiley, 2019)
      Triple-negative breast cancer (TNBC) is characterized by high rates of metastasis and no available molecular targets. CTCs derived xenografts (CDX) have demonstrated to be a promising tool for understanding cancer biology. ...
    • Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression 

      Mota, Alba; Oltra, Sara S.; Selenica, Pier; Moiola, Cristian P.; Casas Arozamena, Carlos; López-Gil, Carlos; Díaz, Eva; Gatius Calderó, Sònia; Ruiz Miró, Maria; Calvo, Ana; Rojo Sebastián, Alejandro; Hurtado, Pablo; Piñeiro, Roberto; Colás, Eva; Gil-Moreno, Antonio; Reis-Filho, Jorge S.; Muinelo-Romay, Laura; Abal, Miguel; Matias-Guiu, Xavier; Weigelt, Britta; Moreno Bueno, Gema (Springer Nature, 2022)
      Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored ...
    • Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer 

      Alonso-Alconada, Lorena; Muinelo-Romay, Laura; Madissoo, Kadri; Díaz-López, Antonio; Krakstad, Camilla; Trovik, Jone; Wik, Elisabeth; Hapangama, Dharani; Coenegrachts, Lieve; Cano, Amparo; Gil-Moreno, Antonio; Chiva, Luís; Cueva, Juan; Vieito, María; Ortega Izquierdo, Maria Eugenia; Mariscal, Javier; Colás, Eva; Castellví, Josep; Cusido, Maite; Dolcet Roca, Xavier; Nijman, Hans W.; Bosse, Tjalling; Green, John A.; Romano, Andrea; Reventós, Jaume; López-López, Rafael; Salvesen, Helga B.; Amant, Frederic; Matias-Guiu, Xavier; Moreno-Bueno, Gema; Abal, Miguel (Biomed Central, 2014)
      Background: About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we ...